iForumRx.org
Avsnitt

The Race is On! Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

iForumRx.org
Dela

For patients with overweight or obesity and type 2 diabetes seeking weight reduction and improved glycemic control, the REDEFINE 2 study supports cagrilintide-semaglutide as an effective option. But is it better than other incretin-based therapies already available?

Guests: Francesca Reilly, PharmD, Rebecca Munger, PharmD, BCACP, and Jason Zupec, PharmD, BCACP

Music by Good Talk

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör American College of Clinical Pharmacy. Innehållet i podden är skapat av American College of Clinical Pharmacy och inte av, eller tillsammans med, Poddtoppen.